As the surge in artificial intelligence reshapes the funding landscape for startups, the biotech sector has shown remarkable resilience, maintaining a consistent investment flow. Over the past few years, financial backing for biotech startups globally has remained relatively stable, typically ranging from $36 billion to $40 billion. Projections indicate that this trend is likely to continue into 2026.
This stability contrasts sharply with the booming overall venture capital investments, which reached unprecedented levels in the first half of this year. However, much of this funding has favored a select few generative AI giants, leaving biotech with a commendable portion of the capital pie.
Significant funding rounds have been highlighted by several biotechs, particularly those at the crossroads of biotechnology and AI. Crunchbase reports that, thus far in 2023, over $6 billion has been directed toward AI-driven biotech firms. The most substantial financing event this year was London’s Isomorphic Labs, which secured a monumental $2.1 billion in a Series B funding round, positioning itself as a leader in AI-led drug design and development.
Following closely was Delaware’s Earendil Labs, which focuses on AI platforms for protein therapeutics, raising $787 million in March. San Francisco’s Chai Discovery, also harnessing AI for drug discovery, garnered $400 million in Series C funding this summer, achieving a valuation of $3.8 billion.
Notably, not all high-funded biotechs this year are solely defined by their AI focus. NewLimit, hailing from South San Francisco, specializes in creating therapies aimed at rejuvenating aging cells and raised $435 million during a Series C in June. To provide a broader perspective, we have compiled a list detailing ten of the most well-funded biotech companies of the year.
While the most prominent funded biotech companies tend to be later-stage entities, the overall investment landscape remains heavily weighted toward early-stage funding. This year, seed and early-stage rounds accounted for over half of all biotech investments, reflecting a trend seen in previous years, where companies often opt for an IPO following Series B or C funding instead of pursuing another round of venture capital.
The biotech sector has also experienced a wave of early public offerings, particularly in promising areas like obesity treatments and pain management. For example, Kailera Therapeutics, which develops therapies for obesity, went public in April, just six months post its Series B. Similarly, personalized medicine company Kardigan debuted on Nasdaq in June after securing over $550 million in early funding the previous year. Latigo Biotherapeutics, focusing on non-opioid chronic pain therapies, completed its IPO in August, approximately a year and a half after its Series B.
Even later-stage biotechs have participated in the IPO momentum, with the largest biotech offering of the year being the ten-year-old Parabilis Medicines, which specializes in cancer therapies and raised its Series F in January.
The current outlook for biotech funding and exits appears robust. Although the atmosphere feels comparatively subdued against the backdrop of the AI investment rush, the growing financial interconnection between AI and biotech suggests that this enthusiasm may start to manifest more prominently in subsequent quarters.
